AKER - Akers Biosciences, Inc.
| Previous Close | 0.5411 |
| Open | 0.5600 |
| Bid | 0.5410 x 49700 |
| Ask | 0.5500 x 104100 |
| Day's Range | 0.5320 - 0.5600 |
| 52 Week Range | 0.1220 - 2.1000 |
| Volume | 2,689,868 |
| Avg. Volume | 16,450,973 |
| Market Cap | 52.789M |
| Beta | -1.15 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6110 |
| Earnings Date | May 14, 2018 - May 18, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
- GlobeNewswire•9 days ago
Akers Biosciences Expands Outsourced US Distribution Capabilities for Heparin PF4 Rapid Test
THOROFARE, N.J., April 12, 2018-- Akers Biosciences, Inc.,, a developer of rapid health information technologies, announces the engagement of two leading Independent Sales Representative organizations ...
- Simply Wall St.•10 days ago
Loss-Making Akers Biosciences Inc (NASDAQ:AKER) Expected To Breakeven
Akers Biosciences Inc’s (NASDAQ:AKER): Akers Biosciences, Inc., together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumersRead More...
- ACCESSWIRE•12 days ago
Free Post Earnings Research Report: AtriCure’s Quarterly Revenues Jumped 11.9%; Net Loss Narrowed
Stock Monitor: Akers Biosciences Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 09, 2018 / Active-Investors.com has just released a free earnings report on AtriCure, Inc. (NASDAQ: ATRC ). If you ...
Markit•17 days agoSee what the IHS Markit Score report has to say about Akers Biosciences Inc.
Short interest is low for AKER with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
- GlobeNewswire•18 days ago
Akers Biosciences Reports Earnings for Fiscal Year 2017
THOROFARE, N.J., April 03, 2018-- Akers Biosciences, Inc.,, a developer of rapid health information technologies, reports its financial results for the fiscal year ended December 31, 2017.. Total revenue ...
- ACCESSWIRE•18 days ago
Akers Biosciences, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / April 3, 2018 / Akers Biosciences, Inc. (NASDAQ: AKER ) will be discussing their earnings results in their Q4 Earnings Call to be held on April 3, 2018, at 9:00 AM Eastern Time. ...
- GlobeNewswire•24 days ago
Akers Biosciences Announces Rescheduled Conference Call to Discuss Fiscal Year 2017 Earnings
THOROFARE, N.J., March 28, 2018-- Akers Biosciences, Inc.,, a developer of rapid health information technologies, will now hold a conference call on Tuesday, April 3, 2018 at 09:00 a.m. Eastern Time to ...
- American City Business Journals•26 days ago
Akers Bio signs 3-year distribution deal with Diagnostica Stago
The agreement covers the South Jersey medical device company's rapid test for detecting HIT.
- ACCESSWIRE•26 days ago
2 Biotech Stocks To Watch After Positive Pre Market News
CORAL GABLES, FL / ACCESSWIRE / March 26, 2018 / Last week, the markets saw a major pullback amid fears of potential trade wars. But heading into Monday's opening bell, optimism is much more prevalent. ...
- Benzinga•26 days ago
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Argenx NV - ADR (NASDAQ: ARGX ) stock was trading ...
- GlobeNewswire•26 days ago
Consolidated Research: 2018 Summary Expectations for Brixmor Property Group, First Majestic Silver, Barclays, Akers Biosciences, Precision Drilling, and NBT — Fundamental Analysis, Key Performance Indications
NEW YORK, March 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- GlobeNewswire•26 days ago
Akers Biosciences Signs US Distribution Agreement with Diagnostica Stago
THOROFARE, N.J., March 26, 2018-- Akers Biosciences, Inc.,, a developer of rapid health information technologies, has entered into a three-year National Distribution Agreement with Diagnostica Stago, Inc. ...
Markit•last monthSee what the IHS Markit Score report has to say about Akers Biosciences Inc.
Short interest is low for AKER with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
- GlobeNewswire•last month
Akers Biosciences Announces Conference Call to Discuss Fiscal Year 2017 Earnings
THOROFARE, N.J, March 15, 2018-- Akers Biosciences, Inc.,, a developer of rapid health information technologies, will hold a conference call on Thursday, March 29, 2018 at 09:00 a.m. Eastern Time to discuss ...
- Simply Wall St.•2 months ago
Did Akers Biosciences Inc’s (NASDAQ:AKER) Earnings Growth Outperform The Industry?
Increase in profitability and industry-beating performance can be essential considerations in a stock for some investors. In this article, I will take a look at Akers Biosciences Inc’s (NASDAQ:AKER) trackRead More...
Markit•2 months agoSee what the IHS Markit Score report has to say about Akers Biosciences Inc.
Short interest is low for AKER with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, ETFs holding AKER are favorable, with net inflows of $338 million.
- ACCESSWIRE•2 months ago
Akers Biosciences Shares Bouncing Back, New Self Diagnostic Products Being Developed
NEW YORK, NY / ACCESSWIRE / February 26, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...
- Reuters•3 months ago
Deals of the day-Mergers and acquisitions
** Facebook Inc is buying a software firm that specializes in authenticating government-issued identification cards, the two companies said, a step that may help the social media company learn more about the people who buy ads on its network. ** Microsemi Corp, the largest U.S. commercial supplier of military and aerospace semiconductor equipment, is exploring its options, including a possible sale, after it received a takeover approach, a person familiar with the matter said. ** The field of prospective bidders for ScotiaMocatta, the metals trading arm of Canada's Bank of Nova Scotia, has narrowed to two, three banking and industry sources said.
Markit•3 months agoSee what the IHS Markit Score report has to say about Akers Biosciences Inc.
Akers Biosciences Inc NASDAQ:AKER
- ACCESSWIRE•3 months ago
Today’s Research Reports on Trending Tickers: Akers Biosciences and InspireMD, Inc.
NEW YORK, NY / ACCESSWIRE / January 10, 2018 / U.S. markets continued to climb to new record highs as we enter into earnings season. Major financial companies, BlackRock, J.P. Morgan Chase and Wells Fargo, ...
- ACCESSWIRE•3 months ago
2 Healthcare Testing & Diagnostic Stocks Taking Center Stage Ahead of JP Morgan Conference
CORAL GABLES, FL / ACCESSWIRE / January 9, 2018 / This week marks the start of JPMorgan's healthcare conference. Investors will be paying close attention to what is revealed and, certainly, the new trends ...
Capital Cube•4 months agoAkers Biosciences, Inc. :AKER-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
Categories: Yahoo FinanceGet free summary analysis Akers Biosciences, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Akers Biosciences, Inc. – OraSure Technologies, Inc., Chembio Diagnostics, Inc., Quidel Corporation and Vermillion, Inc. (OSUR-US, CEMI-US, QDEL-US and VRML-US) that have also reported for this period. Highlights ... Read more (Read more...)
SmarterAnalyst•4 months agoHere’s Why Akers Biosciences Inc (AKER) Shares Are Collapsing
Shares of health testing and screening products maker Akers Biosciences Inc (NASDAQ:AKER) are collapsing – down over 60% as of this writing. Akers announced this morning that it will be selling huge amount of shares of its own stock to raise cash for working capital, product development, marketing activities, expanding its internal sales organization and further developing sales channels and other capital expenditures. The securities offered by the Company consist of (i) Class A Units consisting of 15,500,000 shares of our Common Stock and Warrants to purchase 15,500,000 shares of Common Stock, at a public offering price of $0.15 per Class A Unit, and (ii) Class B Units consisting of 3,675 shares of our Series B Convertible Preferred Stock, with a stated value of $1,000, and convertible into an aggregate of 24,500,000 shares of Common Stock, and Warrants to purchase 24,500,000 shares of Common Stock, at public offering price of $1,000 per Class B Unit.
